Skin toxicity of anti-cancer therapy;Hauttoxizität durch antitumorale therapie

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 11, 2008, Pages 959-975

  Ulrich, Jens ^a   Hartmann, Jörg T ^b   Dörr, Wolfgang ^c   Ugurel, Selma ^d  

^a Department of Dermatology   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Chemotherapy; Cutaneous reactions; Kinase inhibitors; Radiation

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARMUSTINE; CETUXIMAB; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IMATINIB; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PANITUMUMAB; PROCARBAZINE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TENIPOSIDE; THIOTEPA; TIOGUANINE; UNINDEXED DRUG;

ALOPECIA; ANGIONEUROTIC EDEMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; DRY SKIN; ERYTHEMA; HAIR FOLLICLE; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; INDUCED HYPOTHERMIA; INFLAMMATION; LEUKONYCHIA; LEUKONYCHIA STRIATA TRANSVERSALIS; LUNULA HYPERPIGMENTATIO; MONOTHERAPY; NAIL DISCOLORATION; NAIL DISEASE; NAIL HYPERPIGMENTATION; ONYCHOLYSIS; ONYCHOMYCOSIS; PATHOGENESIS; PHOTOTOXICITY; PRURITUS; PSEUDOLYMPHOMA; RADIATION DERMATITIS; RADIATION DOSE; RASH; REVIEW; SEBACEOUS GLAND; SKIN EXFOLIATION; SKIN TOXICITY; SWEAT GLAND; URTICARIA; VASCULITIS;

EID: 55149117750     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06831.x     Document Type: Review

References (78)

1. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002 23 : 205 208.
2. Bolling R, Meyer-Hamme S, Schauder S. Photosensitization with DTIC therapy in metastatic malignant melanoma. Hautarzt 1980 31 : 602 605.
3. Yung CW, Winston EM, Lorincz AL. Dacarbazine-induced photosensitivity reaction. J Am Acad Dermatol 1981 4 : 541 543.
4. Cohen AD, Mermershtain W, Geffen DB, Schoenfeld N, Mamet R, Cagnano E, Cohen Y, Halevy S. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins. J Dermatolog Treat 2005 16 : 19 21.
5. Sun CC, Hsu SC. Photosensitivity from oral administration of a fluorouracil derivative (FT 207). Photodermatol 1984 1 : 94 95.
6. Vukelja SJ, Bonner MW, McCollough M, Cobb PW, Gaule DA, Fanucchi PJ, Keeling JH. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol 1991 25 : 905 908.
7. Breza TS, Halprin KM, Taylor JR. Photosensitivity reaction to vinblastine. Arch Der-matol 1975 111 : 1168 1170.
8. Horn TD, Beveridge RA, Egorin MJ, Abeloff MD, Hood AF. Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol 1989 125 : 524 527.
9. Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994 14 : 449 453.
10. Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer 1996 77 : 1578 1581.
11. Kim KJ, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Periungal hyperpigmentation induced by cisplatin. Clin Exp Dermatol 2002 27 : 118 119.
12. Schrijvers D, Van Den Brande J, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000 142 : 1069 1070.
13. Claudy AL, Levigne V, Boucheron S. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine. Dermatology 1992 184 : 70 72.
14. Mutafoglu-Uysal K, Sarialioglu F, Olgun N. Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor. Turk J Pediatr 2001 43 : 172 174.
15. Cecchi R, Tuci F, Giomi A, Innocenti F. Supravenous hyperpigmentation induced by vinorelbine. Dermatology 1994 188 : 244.
16. Curran CF. Doxorubicin-associated hyperpigmentation. N Z Med J 1990 103 : 517.
17. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004 12 : 543 549.
18. Trueb RM. Praxis der Trichologie. In : Haare. Darmstadt : Steinkopf, 2003 : 199 208.
19. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin On-col 2002 14 : 212 216.
20. Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007 40 : 979 982.
21. Simister JM. Alopecia and cytotoxic drugs. Br Med J 1966 2 : 1138.
22. Pesce A, Cassuto JP, Joyner MV, DuJardin P, Audoly P. Scalp tourniquet in the prevention of chemotherapy-induced alopecia. N Engl J Med 1978 298 : 1204 1205.
23. Forsberg SA. Scalp cooling therapy and cytotoxic treatment. Lancet 2001 357 : 1134.
24. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005 16 : 352 358.
25. Breed WP. What is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss? Support Care Cancer 2004 12 : 3 5.
26. Hussein AM. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol 1995 34 : 470 473.
27. Hussein AM, Stuart A, Peters WP. Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model. Dermatology 1995 190 : 192 196.
28. Ohnemus U, Unalan M, Handjiski B, Paus R. Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. J Invest Dermatol 2004 122 : 7 13.
29. Peters EM, Foitzik K, Paus R, Ray S, Holick MF. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001 117 : 173 178.
30. Schilli MB, Paus R, Menrad A. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 1998 111 : 598 604.
31. Tosti A, Baran R, Dawber RP. The nail in systemic diseases and drug-induced changes. In : Baran R, Dawber RP (eds Diseases of the nails and their management. Oxford : Blackwell Science, 1995 : 175 262.
32. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J. Nail changes secondary to docetaxel (Taxotere). Dermatology 1999 198 : 288 290.
33. Flory SM, Solimando DA Jr., Webster GF, Dunton CJ, Neufeld JM, Haffey MB. Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 1999 33 : 584 586.
34. Ghetti E, Piraccini BM, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 2003 17 : 459 460.
35. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003 14 : 333 337.
36. Rafi L, Friedrich M, Tilgen W, Reichrath J. Severe nail changes due to Docetaxel treatment. Eur J Dermatol 2003 13 : 610 611.
37. Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol 2002 20 : 4404 4405.
38. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R. Docetaxel-induced nail changes - a neurogenic mechanism: a case report. J Neurooncol 2002 58 : 167 174.
39. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005 23 : 4424 4429.
40. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000 1 : 225 234.
41. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007 18 : 1159 1164.
42. Dörr W, Herrmann T, Riesenbeck D. Prävention und Therapie von Nebenwirkungen in der Strahlentherapie. Bremen : Uni-Med Science, 2005.
43. Fajardo LFLG, Berthrong M, Armstrong RE. Radiation pathology. New York : Oxford University Press, 2001.
44. Dörr W. Skin and other reactions to radiotherapy - clinical presentation and radiobi-ology of skin reactions. Front Radiat Ther Oncol 2006 39 : 96 101.
45. Dörr W, Herrmann T. Akute Strahlenveränderungen der Gewebe. In : Bamberg M, Molls M, Sack H (eds Radioonkologie. Band 1: Grundlagen. Germering, München : Zuckschwerdt Verlag GmbH, 2003 : 244 250.
46. Seegenschmiedt H. Management of skin and related reactions to radiotherapy. Front Radiat Ther Oncol 2006 39 : 102 119.
47. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001 61 : 223 231.
48. Campbell IR, Illingworth MH. Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol) 1992 4 : 78 82.
49. Momm F, Weissenberger C, Bartelt S, Henke M. Moist skin care can diminish acute radiation-induced skin toxicity. Strahlenther Onkol 2003 179 : 708 712.
50. Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 2001 58 : 333 339.
51. Bostrom A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol 2001 59 : 257 265.
52. Halperin EC, Gaspar L, George S, Darr D, Pinnell S. A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys 1993 26 : 413 416.
53. Liguori V, Guillemin C, Pesce GF, Mirimanoff RO, Bernier J. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiother Oncol 1997 42 : 155 161.
54. Maiche A, Isokangas OP, Grohn P. Skin protection by sucralfate cream during electron beam therapy. Acta Oncol 1994 33 : 201 203.
55. Roper B, Kaisig D, Auer F, Mergen E, Molls M. Theta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care? Strahlenther Onkol 2004 180 : 315 322.
56. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, MacDougall H, Samuel L, Munro A. Does aqueous or sucralfate cream affect the severity of erythema-tous radiation skin reactions? A randomised controlled trial. Radiother Oncol 2004 73 : 153 162.
57. Mak SS, Molassiotis A, Wan WM, Lee IY, Chan ES. The effects of hydrocolloid dressing and gentian violet on radiation-induced moist desquamation wound healing. Cancer Nurs 2000 23 : 220 229.
58. Lawenda BD, Gagne HM, Gierga DP, Niemierko A, Wong WM, Tarbell NJ, Chen GT, Hochberg FH, Loeffler JS. Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys 2004 60 : 879 887.
59. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005 74 : 121 123.
60. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003 48 : 201 206.
61. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003 88 : 1157 1159.
62. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002 100 : 3434 3435.
63. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood 2003 101 : 2446.
64. Ujiie H, Shimizu T, Shimizu H. Cutaneous reactions to imatinib mesylate treated by topical steroid. Am J Hematol 2005 78 : 246.
65. Schamun A, Bullorsky E, Stemmelin G, Saxton R, Ricchione D. Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy. Blood 2005 105 : 2996 2997.
66. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B. Pooled safety analysis of BAY 43-9006 (so-rafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006 42 : 548 556.
67. Ivanyi P, Winkler T, Ganser A, Reuter C, Grünwald V. Novel Therapies in Advanced Renal Cell Carcinoma: Management of Adverse Events From Sorafenib and Sunitinib. Dtsch Ärztebl 2008 105 : 232 237.
68. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW. Hand-foot skin reaction in patients treated with sorafenib: a clinicopatho-logical study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008 158 : 592 596.
69. Hauschild A, Volkenandt M. Nexavar® beim Nierenzellkarzinom. Kutane Neben-wirkungen und Behandlungsvorschläge. Bayer Health Care 2007 Broschüre).
70. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and sebor-rheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006 24 : 5786 5788.
71. Hartmann JT, Lanz L. Sunitinib causes periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol 2008 in press).
72. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008 358 : 1160 1174.
73. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005 3 : 599 606.
74. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004 22 : 3238 3247.
75. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007 25 : 5390 5396.
76. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, Moon KC, Koh JK. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004 84 : 23 26.
77. Bokemeyer C. Dermatotoxizität antineoplastischer Substanzen. In : Schmoll HJ, Höffken K, Possinger K : Kompendium Internistische Onkologie. 3. Auflage. Berlin, Heidelberg, New York : Springer, 1999.
78. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad DermatolS 1999 40 : 367 398.